Inflammatory Bowel Disease

Obesity correlated with an increased risk for older-age onset Crohn’s disease but not ulcerative colitis, according to research published in Clinical Gastroenterology and Hepatology.

In a video exclusive, Remo Panaccione, MD, University of Calgary, outlined new therapeutic data for the treatment of patients with inflammatory bowel diseases at the 16th Congress of European Crohn’s and Colitis Organisation.

In a video exclusive, Bruce Sands, MD, Icahn School of Medicine, reported Stelara demonstrated sustained remission in adults with moderate to severe ulcerative colitis in the phase 3 UNIFI study long-term extension period.

In a real-world Crohn’s disease population, biologic- naive patients, compared with biologic-experienced patients, had a significantly greater chance for achieving mucosal healing, according to research at Digestive Disease Week.

Model-informed dosing of Entyvio provided data to maximize endoscopic remission rates among patients with Crohn’s disease, according to research published in Inflammatory Bowel Diseases.

Among older patients with inflammatory bowel disease, investigators found deficits in geriatric assessments were highly prevalent, according to a study in Clinical Gastroenterology and Hepatology.

Mucosal biofilms are endoscopic features in patients with irritable bowel syndrome and ulcerative colitis with disrupted bile acid metabolism and bacterial dysbiosis, according to a study in Gastroenterology.

Researchers observed no significant changes in inflammatory bowel disease activity among patients who had COVID-19, according to a study published in Clinical Gastroenterology and Hepatology.

Healio Gastroenterology presents the following reports on the top peer-tested stories in May.

Mirikizumab demonstrated sustained safety and efficacy at 52-weeks in patients with Crohn’s disease; these data support the ongoing VIVID phase 3 study, Bruce Sands, MD, Icahn School of Medicine told Healio Gastroenterology.